Acer Therapeutics Inc. (NASDAQ:ACER – Get Rating) was the recipient of a large increase in short interest in October. As of October 31st, there was short interest totalling 86,100 shares, an increase of 44.5% from the October 15th total of 59,600 shares. Approximately 0.6% of the shares of the company are sold short. Based on an average daily trading volume, of 90,700 shares, the days-to-cover ratio is currently 0.9 days.
Acer Therapeutics Price Performance
Shares of NASDAQ ACER opened at $1.23 on Friday. The stock’s fifty day moving average price is $1.34 and its two-hundred day moving average price is $1.58. Acer Therapeutics has a one year low of $1.11 and a one year high of $3.77. The firm has a market cap of $19.61 million, a price-to-earnings ratio of -0.91 and a beta of 1.21.
Acer Therapeutics (NASDAQ:ACER – Get Rating) last released its earnings results on Monday, August 15th. The biopharmaceutical company reported ($0.48) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.58) by $0.10. On average, equities analysts anticipate that Acer Therapeutics will post -2.63 earnings per share for the current fiscal year.
Institutional Trading of Acer Therapeutics
Acer Therapeutics Company Profile
Acer Therapeutics Inc, a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. Its pipeline includes four clinical-stage candidates comprising EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; ACER-001, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders and maple syrup urine disease; ACER-801 (osanetant) for the treatment of induced Vasomotor Symptoms; and ACER-2820 (emetine), a host-directed therapy against a variety of infectious diseases, including COVID-19.
- Get a free copy of the StockNews.com research report on Acer Therapeutics (ACER)
- MarketBeat: Week in Review 11/7 – 11/11
- Oil Is a Compelling Reason The Sell-Off In Stocks Isn’t Over
- Is Mid-Cap Neurocrine Biosciences A Buy After Blowout Q3 Report?
- Six Flags is a Ride You Don’t Want to Get Stuck On
- Hanesbrands May be Signaling a Bad Week for Retail Stocks
Receive News & Ratings for Acer Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acer Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.